Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.

Research into Cold Cancers Heating Up

Activation and expansion are essential for success in both autologous and allogeneic therapies.

Development of Gamma-Delta T-Cell Therapies

Continuous manufacturing and a quality-by-design development approach are a natural fit.

QbD for Small-Molecule Continuous Process Development

Topic

Articles

The EMA’s annual report shows the agency approved 104 human drugs in 2025 that included first-in-class and first-in-indication therapies. 

EMA Approved 104 Human Medicines in 2025 

GSK boosts oncology pipeline with Nuvalent acquisition, advancing FDA-designated ROS1/ALK inhibitors for NSCLC and expanding kinase inhibitor drug development in lung cancer.

GSK Acquires Nuvalent for $10.6 Billion in Lung Cancer Push

Nicholas Richardson is vice president of clinical development at Precision for Medicine.

Nicholas Richardson, vice president of clinical development at Precision for Medicine, explains why radiopharmaceuticals are unique for patients with cancer and what makes them challenging to develop for those patients. 

Patient Access to Radiopharmaceuticals

J&J and Roche commit billions to protein degrader platforms, signaling a new era in oncology drug development with major manufacturing implications.

Why Big Pharma Is Betting Billions on Protein Degraders for Cancer

Regulatory reform, patient access, and supply chain security were 3 of the key themes showcased this week on PharmTech.com.

PharmTech Weekly Roundup—June 5, 2026

Ajoy Koppolu, PhD, MBA; Pharmaceutical Industry Consultant, NJ 08823

Corresponding email: renewzymes@yahoo.com

The established safety profiles, dosing regimens, and manufacturing pathways of repurposed generics can significantly shorten timelines and reduce costs as alternative cancer therapies.

Renewing Prosaic Generics for Cancer Treatment 

At CPHI Americas, Delaware Gov. Matt Meyer argues domestic pharma manufacturing is a national security priority and positions Delaware as the ideal reshoring hub.

Delaware Governor Meyer on Drug Pricing, Reshoring, and National Security

Kimberly Salgado is Head of Centre for Biosimilar Drug Development, ICON plc

Changes in regulations are reducing costs, expediting approval, and increasing the market for biosimilars.

Faster Doesn’t Mean Easier: Development Impacts of a New Biosimilar Regulatory Landscape

EMA, AMA, and national regulatory authorities in Africa are working on potential clinical trial designs and medical treatments for the Ebola outbreak in the DRC and Uganda.

EMA Collaborates with African Regulators on Ebola Treatments

The organization’s set of product-specific biologics emerging standards are available on its Emerging Standards Platform for public comment.